165 related articles for article (PubMed ID: 24849812)
1. Switch in FOXA1 status associates with endometrial cancer progression.
Tangen IL; Krakstad C; Halle MK; Werner HM; Oyan AM; Kusonmano K; Petersen K; Kalland KH; Akslen LA; Trovik J; Hurtado A; Salvesen HB
PLoS One; 2014; 9(5):e98069. PubMed ID: 24849812
[TBL] [Abstract][Full Text] [Related]
2. Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas.
Droog M; Nevedomskaya E; Kim Y; Severson T; Flach KD; Opdam M; Schuurman K; Gradowska P; Hauptmann M; Dackus G; Hollema H; Mourits M; Nederlof P; van Boven H; Linn SC; Wessels L; van Leeuwen FE; Zwart W
Cancer Res; 2016 Jul; 76(13):3773-84. PubMed ID: 27197147
[TBL] [Abstract][Full Text] [Related]
3. Forkhead-box A1 suppresses the progression of endometrial cancer via crosstalk with estrogen receptor α.
Wang J; Bao W; Qiu M; Liao Y; Che Q; Yang T; He X; Qiu H; Wan X
Oncol Rep; 2014 Mar; 31(3):1225-34. PubMed ID: 24452315
[TBL] [Abstract][Full Text] [Related]
4. Forkhead box transcription factor, forkhead box A1, shows negative association with lymph node status in endometrial cancer, and represses cell proliferation and migration of endometrial cancer cells.
Abe Y; Ijichi N; Ikeda K; Kayano H; Horie-Inoue K; Takeda S; Inoue S
Cancer Sci; 2012 Apr; 103(4):806-12. PubMed ID: 22313737
[TBL] [Abstract][Full Text] [Related]
5. FOXA1 antagonizes EZH2-mediated CDKN2A repression in carcinogenesis.
Zhang Y; Tong T
Biochem Biophys Res Commun; 2014 Oct; 453(1):172-8. PubMed ID: 25264199
[TBL] [Abstract][Full Text] [Related]
6. Loss of GPER identifies new targets for therapy among a subgroup of ERα-positive endometrial cancer patients with poor outcome.
Krakstad C; Trovik J; Wik E; Engelsen IB; Werner HM; Birkeland E; Raeder MB; Øyan AM; Stefansson IM; Kalland KH; Akslen LA; Salvesen HB
Br J Cancer; 2012 May; 106(10):1682-8. PubMed ID: 22415229
[TBL] [Abstract][Full Text] [Related]
7. Androgen receptor as potential therapeutic target in metastatic endometrial cancer.
Tangen IL; Onyango TB; Kopperud R; Berg A; Halle MK; Øyan AM; Werner HM; Trovik J; Kalland KH; Salvesen HB; Krakstad C
Oncotarget; 2016 Aug; 7(31):49289-49298. PubMed ID: 27384477
[TBL] [Abstract][Full Text] [Related]
8. LncRNA DSCAM-AS1 interacts with YBX1 to promote cancer progression by forming a positive feedback loop that activates FOXA1 transcription network.
Zhang Y; Huang YX; Wang DL; Yang B; Yan HY; Lin LH; Li Y; Chen J; Xie LM; Huang YS; Liao JY; Hu KS; He JH; Saw PE; Xu X; Yin D
Theranostics; 2020; 10(23):10823-10837. PubMed ID: 32929382
[No Abstract] [Full Text] [Related]
9. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
[TBL] [Abstract][Full Text] [Related]
10. FOXA1 levels are decreased in pleural breast cancer metastases after adjuvant endocrine therapy, and this is associated with poor outcome.
Schrijver W; Schuurman K; van Rossum A; Droog M; Jeronimo C; Salta S; Henrique R; Wesseling J; Moelans C; Linn SC; van den Heuvel M; van Diest P; Zwart W
Mol Oncol; 2018 Nov; 12(11):1884-1894. PubMed ID: 29972720
[TBL] [Abstract][Full Text] [Related]
11. Expression of glucocorticoid receptor is associated with aggressive primary endometrial cancer and increases from primary to metastatic lesions.
Tangen IL; Veneris JT; Halle MK; Werner HM; Trovik J; Akslen LA; Salvesen HB; Conzen SD; Fleming GF; Krakstad C
Gynecol Oncol; 2017 Dec; 147(3):672-677. PubMed ID: 28927900
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of Forkhead box protein A1 (FOXA1) leads to cancer stem cell-like properties in tamoxifen-resistant breast cancer cells through induction of interleukin-6.
Yamaguchi N; Nakayama Y; Yamaguchi N
J Biol Chem; 2017 May; 292(20):8136-8148. PubMed ID: 28270510
[TBL] [Abstract][Full Text] [Related]
13. Twist1 promotes breast cancer invasion and metastasis by silencing Foxa1 expression.
Xu Y; Qin L; Sun T; Wu H; He T; Yang Z; Mo Q; Liao L; Xu J
Oncogene; 2017 Feb; 36(8):1157-1166. PubMed ID: 27524420
[TBL] [Abstract][Full Text] [Related]
14. Impact of GATA-3 and FOXA1 expression in patients with hormone receptor-positive/HER2-negative breast cancer.
Hisamatsu Y; Tokunaga E; Yamashita N; Akiyoshi S; Okada S; Nakashima Y; Taketani K; Aishima S; Oda Y; Morita M; Maehara Y
Breast Cancer; 2015 Sep; 22(5):520-8. PubMed ID: 24415069
[TBL] [Abstract][Full Text] [Related]
15. Analyses of an epigenetic switch involved in the activation of pioneer factor FOXA1 leading to the prognostic value of estrogen receptor and FOXA1 co-expression in breast cancer.
Jing X; Liang H; Hao C; Hongxia L; Cui X
Aging (Albany NY); 2019 Sep; 11(18):7442-7456. PubMed ID: 31562808
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-93 Promotes Epithelial-Mesenchymal Transition of Endometrial Carcinoma Cells.
Chen S; Chen X; Sun KX; Xiu YL; Liu BL; Feng MX; Sang XB; Zhao Y
PLoS One; 2016; 11(11):e0165776. PubMed ID: 27829043
[TBL] [Abstract][Full Text] [Related]
17. KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer.
Birkeland E; Wik E; Mjøs S; Hoivik EA; Trovik J; Werner HM; Kusonmano K; Petersen K; Raeder MB; Holst F; Øyan AM; Kalland KH; Akslen LA; Simon R; Krakstad C; Salvesen HB
Br J Cancer; 2012 Dec; 107(12):1997-2004. PubMed ID: 23099803
[TBL] [Abstract][Full Text] [Related]
18. The prognostic relevance of FOXA1 and Nestin expression in breast cancer metastases: a retrospective study of 164 cases during a 10-year period (2004-2014).
De Lara S; Nyqvist J; Werner Rönnerman E; Helou K; Kenne Sarenmalm E; Einbeigi Z; Karlsson P; Parris TZ; Kovács A
BMC Cancer; 2019 Feb; 19(1):187. PubMed ID: 30819139
[TBL] [Abstract][Full Text] [Related]
19. FOXA1 promotes tumor cell proliferation through AR involving the Notch pathway in endometrial cancer.
Qiu M; Bao W; Wang J; Yang T; He X; Liao Y; Wan X
BMC Cancer; 2014 Feb; 14():78. PubMed ID: 24512546
[TBL] [Abstract][Full Text] [Related]
20. FOXA1 is essential for aryl hydrocarbon receptor-dependent regulation of cyclin G2.
Ahmed S; Al-Saigh S; Matthews J
Mol Cancer Res; 2012 May; 10(5):636-48. PubMed ID: 22596188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
